Full-Time
Field Service Engineer
Posted on 7/15/2025
Selux Diagnostics
11-50 employees
Rapid antibiotic susceptibility testing for hospitals
Compensation Overview
$60k - $110k/yr
Boston, MA, USA
In Person
Travel 60-90% of the time; must lift 50–75 lbs; onsite training may be required at headquarters in Boston.
 Medical, Clinical & Veterinary (1) |
|---|
- You must be able to routinely lift medical equipment weighing up to 50-75 pounds.
- This position requires you to travel 60-90% of the time, often with short notice.
- You must have open availability Monday through Friday.
- You must be available to train onsite at the company's headquarters in Boston as needed.
- High school diploma and at least 2 years of technical school, equivalent military training, or equivalent work experience.
- An active and unrestricted driver license is required for this position.
- Serve as a high-level resource and expert in installation, testing, and updating medical devices.
- Serve as customer contact for complex technical and service-related problems and determine the most cost-effective repair/resolution to minimize customer downtime.
- Drive the sense of urgency to ensure customer needs are addressed promptly with an emphasis on a 'first time fix'.
- Close service calls upon completion.
- Provide reports for analysis of failure trends and serviceability issues and document all activity in a manner compliant with the company's quality procedures.
- Contribute to the development of Selux's best practices in customer service and service ability.
- Configure software and network products within hospital laboratories.
- Other duties as assigned.
- Lives in either Texas or Illinois.
- Four-year college degree preferred.
- An active and unrestricted driver license is required for this position.
- Comfortable with basic software programs and Microsoft operating system.
- Proficiency in assembling and disassembling diverse equipment and devices.
- Knowledge of electronics, electro-mechanical systems, and information technology.
- Ability to sit and stand for extended periods of time and lift a weight up to 75 pounds.
- Experience in healthcare, field service, engineering, biomedical, maintenance, customer service, electronics, electrical, technical work, and IT is beneficial for this position.
- Knowledge of basic biology/chemistry.
- Good written/verbal communication, organization, and prioritization skills.
- Effective customer service skills and a positive attitude.
- Flexibility and adaptability to change as it occurs regularly for a Field Service Engineer throughout her/his day/week.
- Self-motivation and ability to manage a dynamic schedule.
- This is an overtime eligible hourly position with a target annual range of $60K-110K.
Selux Diagnostics provides rapid, comprehensive antibiotic susceptibility testing (AST) to hospitals and healthcare providers. It helps identify which antibiotics will effectively treat a bacterial infection by testing against all commercially relevant antibiotics at once, enabling faster and more accurate prescription decisions. By delivering quicker results and updating interpretive breakpoints, Selux addresses antimicrobial resistance and preserves antibiotic effectiveness. The company differentiates itself through its ability to run broad-spectrum AST in a single assay, improving turnaround times and coverage compared with traditional AST methods. Its goal is to reduce inappropriate antibiotic use in hospitals, lower AMR risks, and save lives by ensuring patients receive the right antibiotic therapy sooner.
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$252.4M
Headquarters
Boston, Massachusetts
Founded
2014
Simplify's Take
What believers are saying
- Same-day AST results reduce broad-spectrum antibiotic overuse and combat antimicrobial resistance epidemic.
- $48M Series funding round in April 2024 accelerates U.S. commercialization and market expansion.
- FDA Breakthrough Device Designation and three 510(k) clearances validate NGP platform's clinical utility.
What critics are saying
- Accelerate Diagnostics' qPCR systems deliver results in under 2 hours versus Selux's 5.5 hours.
- BD and Copan's integrated workflows lock hospitals into competing ecosystems, blocking NGP adoption.
- FDA post-market studies reveal 5–10% categorical errors in NGP versus gold-standard BMD testing.
What makes Selux Diagnostics unique
- Only single-platform technology delivering rapid AST from positive blood cultures and isolated colonies simultaneously.
- Proprietary Viability and Surface Area Assays detect dying cells without waiting for cell death.
- 384-well panel enables comprehensive testing against all commercially relevant antibiotics at once.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Company Match
Unlimited Paid Time Off
Parental Leave
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↓ -10%2 year growth
↑ 5%Arlington, Va.-based Sands Capital has joined a $48 million funding round for Selux Diagnostics, a biotech startup promising personalized therapies.
This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
SeLux Diagnostics has filed a notice of an exempt offering of securities to raise $45,000,000.00 in New Debt Financing. SeLux Diagnostics has filed a notice of an exempt offering of securities to raise $45,000,000.00 in New Debt Financing.According to filings with the U.S. Securities and Exchange Commission, SeLux Diagnostics is raising up to $45,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Steve Lufkin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About SeLux DiagnosticsSelux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the worlds deadliest and costliest health threats
SeLux Dx: The company raised $40 million of venture funding in the form of convertible debt from undisclosed investors on February 13, 2024.
Approval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies. . .